

# Midatech Pharma PLC

07:36 20 Sep 2019

## Midatech Pharma gets green light for additional trial

Midatech Pharma PLC (LON: MTPH; NASDAQ:MTP) said it had received the regulatory green light for a trial that may eventually pave the way for its long-acting drug to be administered by patients at home.

MTD201 has already negotiated a phase I study which showed it to have significant advantages over Novartis' Sandostatin LAR, the current standard of care.

The treatment is being developed for people suffering acromegaly, where the body produces too much growth hormone, and neuroendocrine tumours, which affect hormone-releasing cells and can sometimes be cancerous.

The point of the additional trial is to assess the delivery mechanism.

Midatech wants to see whether it is clinically effective administering MTD201 via a subcutaneous injection, which means going into a layer of the skin rather than muscle.

Using this method would reduce the pain of the jab and "allow the potential for self-administration at home without the need to for hospital visits to receive drug injections".

Data from the trial on 28 healthy people will be available towards the end of the year, or early 2020, ahead of the pivotal registration study next year.

MTD201 incorporates the company's Q-Sphera sustained release technology.

**Price:** 20

**Market Cap:** £7.85 m

### 1 Year Share Price Graph



### Share Information

**Code:** MTPH

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	162	15

**Sector:** Pharma & Biotech

**Website:** [www.midatechpharma.com](http://www.midatechpharma.com)

### Company Synopsis:

*Midatech is fully focussed on enhancing and extending the lives of patients with rare and serious cancers. We have built an organization distinguished by world-class scientists with a talent for developing and applying our novel drug delivery technologies to improve existing, or develop new, treatments for these diseases.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.